+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Inflammatory biomarkers in metastatic colorectal cancer: prognostic and predictive role beyond the first line setting



Inflammatory biomarkers in metastatic colorectal cancer: prognostic and predictive role beyond the first line setting



Oncotarget 8(56): 96048-96061



Inflammatory biomarkers are useful prognostic tools in cancer patients. However, the prognostic and predictive value of inflammatory biomarkers beyond the 1st-line setting in metastatic colorectal cancer (mCRC) is unclear. In multivariate analysis 1 standard deviation increase in neutrophil-lymphocyte-ratio (NLR) was associated with an 8.5% absolute lower objective-response-rate (ORR) in 1st-line (p<0.0001), 3% lower ORR in 2nd-line (p< 0.0001), and 3% lower ORR in 3rd-line (p=0.24), respectively. Regarding progression free survival (PFS), an increase in the NLR was significantly associated with rising hazard-ratios (HR) over all treatment lines (HR=1.30, p= 0.021 1st-line); (HR=1.37, p<0.0001 2nd-line); (HR=1.44, p=0.042 3rd-line). The platelet-lymphocyte-ratio (PLR) was associated with 6-month PFS over all three treatment lines. Higher C-reactive-protein (CRP) predicted for worse PFS in the first two chemotherapy lines and in best supportive care (BSC). (HR=1.49 (p<0.0001 1st-line); HR=1.25 (p=0.007 2nd-line); HR=1.09 (95%CI 0.81-1.48, p=0.552 3rd-line and HR=1.43 (p= 0.002 in BSC)). Two-hundred-fifty-eight patients with mCRC undergoing palliative chemo(immuno-)therapy were retrospectively included. Primary endpoints were 6-month PFS and ORR during 1st-line, 2nd-line, and 3rd-line treatment, and 6-month overall survival during BSC. This study shows that inflammatory biomarkers are useful predictors of disease outcome and treatment response over several treatment lines in mCRC patients.

(PDF emailed within 1 workday: $29.90)

Accession: 065236883

Download citation: RISBibTeXText

PMID: 29221186


Related references

Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer 17(4): E687-E697, 2018

Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer. Clinical Colorectal Cancer 9(5): 274-281, 2011

Prognostic and Predictive Biomarkers in Colorectal Cancer. From the Preclinical Setting to Clinical Practice. Current Cancer Drug Targets 15(8): 703-715, 2016

Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy. World Journal of Gastroenterology 22(30): 6944-6954, 2017

Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer. International Journal of Cancer 135(3): 731-741, 2014

Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. Journal of Clinical Oncology 31(6): 759-765, 2013

Synergistic role of Cul1 and c-Myc: Prognostic and predictive biomarkers in colorectal cancer. Oncology Reports 38(1): 245-252, 2017

The Prognostic and Predictive Value of Carbohydrate Antigen 19-9 in Metastatic Colorectal Cancer Patients with First Line Bevacizumab Containing Chemotherapy. Journal of Cancer 8(8): 1410-1416, 2017

Prognostic role of inflammatory biomarkers in metastatic breast cancer. Journal of B.U.On. 22(3): 614-622, 2017

Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. International Journal of Cancer 136(1): 83-90, 2014

Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers. Cancer Medicine 2019, 2019

Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO. Annals of Oncology 29(4): 924-930, 2018

Synergistic role of Caspase-8 and Caspase-3 expressions: Prognostic and predictive biomarkers in colorectal cancer. Cancer Biomarkers 21(4): 899-908, 2018

Prognostic biomarkers for metastatic colorectal cancer. Der Pathologe 37(Suppl 2): 180-185, 2016

RAS Mutations as Predictive Biomarkers in Clinical Management of Metastatic Colorectal Cancer. Clinical Colorectal Cancer 15(2): 95-103, 2017